0
0
A recent large-scale study has shown that Amgen’s cholesterol-lowering drug Repatha can significantly reduce the risk of a first major cardiovascular event, including heart attack and stroke, by 25% in patients at risk but who have never experienced such an event before. This milestone represents the first time a PCSK9 inhibitor drug has demonstrated effectiveness in primary prevention of cardiovascular disease, expanding treatment options for a broader group of patients.
Key Findings
The study, involving more than 12,000 participants, revealed that adding Repatha to standard therapy lowered the risk of a first heart attack by 36%. The trial also showed a 21% reduction in cardiovascular death, although the mortality benefit did not reach statistical significance. The results were presented at the American Heart Association’s 2025 scientific conference in New Orleans.
How Repatha Works
Repatha targets a protein called PCSK9 which regulates LDL cholesterol (“bad” cholesterol) levels in the bloodstream. By inhibiting PCSK9, Repatha enables the liver to remove more LDL cholesterol, particularly benefiting patients who do not respond sufficiently to traditional statins that block cholesterol production in the liver. Elevated LDL cholesterol is a major risk factor for atherosclerosis, which can lead to heart attacks and strokes.
Expert Perspectives
Jay Bradner, Amgen’s chief of research and development, highlighted the significance of these findings, stating that having robust data is crucial for healthcare payers to support wider coverage of the drug. Dr. Elizabeth McNally, a cardiologist and human geneticist not involved in the study, noted that these results represent an important advance in preventing primary cardiovascular events but cautioned that long-term benefits and comparisons to existing therapies require further evaluation.
Context and Implications for Public Health
Cardiovascular disease remains the leading cause of death globally. The FDA expanded Repatha’s approval in August 2025 to include adults at increased risk for events due to uncontrolled LDL cholesterol, removing the earlier restriction that required an established cardiovascular disease diagnosis. This approval makes preventive intervention more accessible to patients who are at high risk but have not yet suffered a heart attack or stroke.
Patients who struggle with statin intolerance or insufficient cholesterol control may particularly benefit from adding Repatha to their regimen. Given that roughly a quarter of U.S. adults have dangerously high LDL levels exceeding 130 mg/dL, this therapy could help reduce a significant burden of preventable cardiovascular events.
Practical Considerations
Repatha is administered as an injection, with cost considerations playing a role in accessibility. Recently, Amgen lowered the out-of-pocket price for direct-to-consumer sales in the U.S. to $239 per month, making it more affordable compared to the previous list price of $573. This pricing adjustment may encourage broader adoption among appropriate patients.
Potential Limitations and Balanced Viewpoints
While this study demonstrates promising benefits, the modest reduction in cardiovascular mortality did not reach statistical significance, indicating the need for further research. Additionally, expert cardiologists have expressed caution, underscoring the importance of long-term safety data and comparative effectiveness relative to other treatment options such as newer oral cholesterol-lowering drugs under development.
Moreover, adherence to current guideline-recommended therapies, including lifestyle modifications and statins, remains essential. Repatha’s role should be considered as part of a comprehensive cardiovascular risk management plan tailored to individual patient needs.
Medical Disclaimer:
This article is for informational purposes only and should not be considered medical advice. Always consult with qualified healthcare professionals before making any health-related decisions or changes to your treatment plan. The information presented here is based on current research and expert opinions, which may evolve as new evidence emerges.
References:
